NO340204B1 - 4-hydroksybenzomorfaner - Google Patents

4-hydroksybenzomorfaner Download PDF

Info

Publication number
NO340204B1
NO340204B1 NO20072839A NO20072839A NO340204B1 NO 340204 B1 NO340204 B1 NO 340204B1 NO 20072839 A NO20072839 A NO 20072839A NO 20072839 A NO20072839 A NO 20072839A NO 340204 B1 NO340204 B1 NO 340204B1
Authority
NO
Norway
Prior art keywords
hydrogen
compound according
mmol
hydroxy
disease
Prior art date
Application number
NO20072839A
Other languages
English (en)
Norwegian (no)
Other versions
NO20072839L (no
Inventor
Mark P Wentland
Original Assignee
Rensselaer Polytech Inst
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rensselaer Polytech Inst filed Critical Rensselaer Polytech Inst
Publication of NO20072839L publication Critical patent/NO20072839L/no
Publication of NO340204B1 publication Critical patent/NO340204B1/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/26—Benzomorphans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D215/14—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D215/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/22—Bridged ring systems
    • C07D221/28—Morphinans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/02—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with oxygen atoms attached in positions 3 and 6, e.g. morphine, morphinone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/06—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: with a hetero atom directly attached in position 14
    • C07D489/08—Oxygen atom

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Addiction (AREA)
  • Immunology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Obesity (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Other In-Based Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Hydrogenated Pyridines (AREA)
NO20072839A 2004-11-05 2007-06-04 4-hydroksybenzomorfaner NO340204B1 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62534804P 2004-11-05 2004-11-05
PCT/US2005/039911 WO2006052710A1 (en) 2004-11-05 2005-11-03 4-hydroxybenzomorphans

Publications (2)

Publication Number Publication Date
NO20072839L NO20072839L (no) 2007-08-03
NO340204B1 true NO340204B1 (no) 2017-03-20

Family

ID=36128632

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20072839A NO340204B1 (no) 2004-11-05 2007-06-04 4-hydroksybenzomorfaner

Country Status (20)

Country Link
US (7) US7262298B2 (https=)
EP (2) EP2251330B1 (https=)
JP (3) JP5198067B2 (https=)
KR (1) KR101115841B1 (https=)
CN (1) CN101090891B (https=)
AT (1) ATE557006T1 (https=)
AU (1) AU2005304950B2 (https=)
BR (1) BRPI0517091B8 (https=)
CA (1) CA2587074C (https=)
CY (1) CY1112946T1 (https=)
DK (1) DK2251330T3 (https=)
ES (1) ES2387737T3 (https=)
IL (1) IL182983A (https=)
MX (1) MX2007005389A (https=)
NO (1) NO340204B1 (https=)
PL (1) PL2251330T3 (https=)
PT (1) PT2251330E (https=)
RU (2) RU2480455C2 (https=)
SI (1) SI2251330T1 (https=)
WO (1) WO2006052710A1 (https=)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002227135B2 (en) * 2000-10-31 2008-01-03 Rensselaer Polytechnic Institute 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
ES2387737T3 (es) * 2004-11-05 2012-10-01 Rensselaer Polytechnic Institute 4-Hidroxibenzomorfanos
JP5266051B2 (ja) 2005-07-21 2013-08-21 レンセラール ポリテクニック インスティチュート 大きい置換基を有する非フェノール性オピオイド
CA2637610A1 (en) 2007-05-04 2008-11-04 Mallinckrodt Inc. Improved process for the preparation of 6-alpha-hydroxy-n-alkylated opiates
CA2693436A1 (en) 2007-07-17 2009-01-22 Christopher W. Grote Preparation of n-alkylated opiates by reductive amination
CN101827819B (zh) 2007-08-09 2013-06-12 伦斯勒理工学院 阿片样物质酰胺季铵盐
CN102227434B (zh) 2008-09-30 2015-02-18 马林克罗特有限公司 选择性胺化酮吗啡喃的方法
US8946419B2 (en) 2009-02-23 2015-02-03 Mallinckrodt Llc (+)-6-hydroxy-morphinan or (+)-6-amino-morphinan derivatives
EP3170395A1 (en) * 2009-03-19 2017-05-24 Alkermes Pharma Ireland Limited Morphinan derivatives with high oral bioavailability
US20100261906A1 (en) * 2009-04-09 2010-10-14 Mallinckrodt Inc. Preparation of 6-Keto, 3-Alkoxy Morphinans
PL2440562T3 (pl) 2009-06-11 2017-07-31 Mallinckrodt Llc Otrzymywanie 6-alfa-amino-N-podstawionych morfinanów w wyniku katalitycznego przeniesienia wodoru
EP2440561B1 (en) 2009-06-11 2014-04-30 Mallinckrodt LLC Reductive amination of 6-keto normorphinans by catalytic hydrogen transfer
TR201908514T4 (tr) * 2009-12-04 2019-07-22 Alkermes Pharma Ireland Ltd İlaç doz aşimi tedavi̇si̇ i̇çi̇n morfi̇nan türevleri̇
US8436175B2 (en) 2010-03-22 2013-05-07 Rensselaer Polytechnic Institute Carboxamide bioisosteres of opiates
WO2011137086A1 (en) * 2010-04-29 2011-11-03 Mallinckrodt Llc Preparation of saturated ketone morphinan compounds having low metal content
CA2804940C (en) 2010-07-08 2017-03-07 Alkermes Pharma Ireland Limited Process for the synthesis of substituted morphinans
US8778960B2 (en) * 2010-08-23 2014-07-15 Alkermes Pharma Ireland Limited Methods for treating antipsychotic-induced weight gain
WO2012138888A1 (en) 2011-04-05 2012-10-11 Alkermes, Inc. Process for the synthesis of quaternary amine compounds
EP2718294B1 (en) 2011-06-09 2018-09-05 SpecGx LLC Reductive amination of 6-keto morphinans by catalytic hydrogen transfer
WO2013003720A1 (en) 2011-06-29 2013-01-03 Alkermes, Inc. Peripherally acting opioid compounds
CN103917543A (zh) 2011-09-08 2014-07-09 马林克罗特有限公司 在不分离中间体的情况下制备生物碱
LT3153171T (lt) 2011-12-15 2018-12-10 Alkermes Pharma Ireland Limited Samidorfanas (alks 33) derinyje su buprenorfinu, skirtas depresinių sutrikimų gydymui
US9211293B2 (en) 2011-12-15 2015-12-15 Alkermes Pharma Ireland Limited Opioid agonist antagonist combinations
EP3003311A2 (en) 2013-05-24 2016-04-13 Alkermes Pharma Ireland Limited Methods for treating depressive symptoms
ES2770978T3 (es) 2013-05-24 2020-07-06 Alkermes Pharma Ireland Ltd Análogos de morfanos y morfinanos y métodos de uso
CN110352055A (zh) * 2017-03-02 2019-10-18 株式会社三和化学研究所 酒精使用障碍的治疗药物
CN107089948B (zh) * 2017-04-28 2020-07-17 云南大学 吗吩衍生物及其制备方法和应用
CN111978252A (zh) * 2019-05-21 2020-11-24 复旦大学 手性苯并吗吩烷类衍生物及其制备方法和在药学上的应用
TW202140009A (zh) * 2020-02-13 2021-11-01 大陸商上海翰森生物醫藥科技有限公司 ３－甲醯胺基－４－羥基納曲酮氘代衍生物、其製備方法及其在醫藥上的應用
CN111205151B (zh) * 2020-02-29 2021-03-05 深圳市祥根生物科技有限公司 一种布洛芬杂质i的环保制备方法
EP4243768A1 (en) 2020-11-12 2023-09-20 Alkermes Pharma Ireland Limited Immediate release multilayer tablet
CN114621238B (zh) * 2020-12-10 2026-02-03 鲁南制药集团股份有限公司 一种制备纳呋拉啡的方法
KR102663533B1 (ko) * 2021-11-09 2024-05-08 백미선 레이저 치료기기용 온냉각장치

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187009A1 (en) * 2000-10-31 2003-10-02 Wentland Mark P. 8-carboxamido-2,6-methano-3-benzazocines

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4032529A (en) * 1974-09-20 1977-06-28 Sterling Drug Inc. Aminomethanobenzazocine intermediates
US3957793A (en) * 1974-09-20 1976-05-18 Sterling Drug Inc. Hydroxyiminobenzazocines
SU635868A3 (ru) * 1974-11-12 1978-11-30 Бристол Мейерз Компани (Фирма) Способ получени морфиновых производных или их солей
US4205171A (en) * 1976-01-12 1980-05-27 Sterling Drug Inc. Aminomethanobenzazocines and nitromethanobenzazocines
US4373139A (en) * 1979-04-30 1983-02-08 Motorola, Inc. Detectors
US4649200A (en) * 1986-05-08 1987-03-10 Regents Of The University Of Minnesota Substituted pyrroles with opioid receptor activity
EP0632041A1 (en) 1993-07-01 1995-01-04 Katholieke Universiteit Nijmegen New morphine derivatives having improved analgesic and narcotic properties
ATE229958T1 (de) 1996-01-10 2003-01-15 Glaxosmithkline Spa Heterocyclische kondensierte morphin-derivate
WO2004007449A1 (en) 2002-07-16 2004-01-22 Rensselaer Polytechnic Institute Process for conversion of phenols to carboxamides via the succinimide esters
ES2387737T3 (es) * 2004-11-05 2012-10-01 Rensselaer Polytechnic Institute 4-Hidroxibenzomorfanos

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030187009A1 (en) * 2000-10-31 2003-10-02 Wentland Mark P. 8-carboxamido-2,6-methano-3-benzazocines

Also Published As

Publication number Publication date
KR101115841B1 (ko) 2012-03-09
CY1112946T1 (el) 2016-04-13
PL2251330T3 (pl) 2012-12-31
US8802655B2 (en) 2014-08-12
US7262298B2 (en) 2007-08-28
US20070238748A1 (en) 2007-10-11
JP2008519035A (ja) 2008-06-05
JP5198067B2 (ja) 2013-05-15
RU2007120759A (ru) 2008-12-10
CN101090891A (zh) 2007-12-19
JP2016020364A (ja) 2016-02-04
BRPI0517091B1 (pt) 2019-10-08
MX2007005389A (es) 2007-12-07
US8680112B2 (en) 2014-03-25
US20160075658A1 (en) 2016-03-17
KR20070085723A (ko) 2007-08-27
BRPI0517091A (pt) 2008-09-30
IL182983A (en) 2012-06-28
ES2387737T3 (es) 2012-10-01
AU2005304950B2 (en) 2010-12-09
RU2415131C2 (ru) 2011-03-27
WO2006052710A1 (en) 2006-05-18
RU2480455C2 (ru) 2013-04-27
JP2013067636A (ja) 2013-04-18
EP2251330B1 (en) 2012-05-09
US20140148475A1 (en) 2014-05-29
PT2251330E (pt) 2012-07-20
CA2587074A1 (en) 2006-05-18
CN101090891B (zh) 2012-08-01
JP6058981B2 (ja) 2017-01-11
EP2251330A1 (en) 2010-11-17
US20060111384A1 (en) 2006-05-25
US20150011768A1 (en) 2015-01-08
CA2587074C (en) 2012-09-04
US20130231361A1 (en) 2013-09-05
EP1817291A1 (en) 2007-08-15
US20240092740A1 (en) 2024-03-21
RU2010147915A (ru) 2012-05-27
DK2251330T3 (da) 2012-08-06
IL182983A0 (en) 2007-08-19
NO20072839L (no) 2007-08-03
SI2251330T1 (sl) 2012-09-28
ATE557006T1 (de) 2012-05-15
AU2005304950A1 (en) 2006-05-18
BRPI0517091B8 (pt) 2021-05-25

Similar Documents

Publication Publication Date Title
NO340204B1 (no) 4-hydroksybenzomorfaner
US6784187B2 (en) 8-carboxamido-2,6-methano-3-benzazocines
JP5581211B2 (ja) 第四級オピオイドカルボキサミド
AU2002227135A1 (en) 8- substituted-2, 6-methano-3-benzazocines and 3-substituted morphinanes as opioid receptor binding agents
CA2686851A1 (en) Fused-ring heterocycle opioids
AU2006272773B2 (en) 8-carboxamido-substituted-2 , 6-methano-3-benzazocines and 3 - carboxamido- substituted morphanes as opioid receptor binding agents